Volume 62, Numéro 3, Mai-Juin 2007XXIIes Rencontres Nationales de Pharmacologie Clinique, Giens 7-10 octobre 2006
|Page(s)||245 - 247|
|Publié en ligne||6 septembre 2007|
Which Pharmacovigilance for Vaccines?
Service de Pharmacologie, Hôpital Henri Mondor, Paris, France
2 sanofi pasteur, Lyon, France
3 Service de Pharmacologie, Hôpital Pellegrin Carreire, Bordeaux, France
Vaccines are not separate health products but anti-infectious medicines administered for the large part prophylactically and for which the effect is immunological and not pharmacological. They should be evaluated by the usual methods of clinical pharmacology and pharmacovigilance, taking into account certain specificities (mechanism of action, manufacture, frequent administration to healthy subjects, particular recommendations, etc.). Experience from some vaccination campaigns have revealed insufficiencies notably in data collection allowing evaluation of the interest of a vaccine to public health, its relevance to the recent epidemiology of the disease in question and long-term security. The absence of data can generate fear in the general population that is broadcast by anti-vaccination lobby. For a more optimal pharmacovigilance of vaccines, it is necessary to: (i) improve the coherence between the evaluating authorities; (ii) set up, in addition to the usual risk management plan, an active microbiological and epidemiological surveillance and to follow up exposed populations; (iii) have programmes of education of the medical community regarding vaccination and health education for the general public.
Key words: vaccines / pharmacovigilance / epidemiology
© Société Française de Pharmacologie et de Thérapeutique, 2007